Meta Analysis Of Huangkui Capsule Combined With Valsartan In The Treatment Of Diabetic Kidney Disease

Purpose: To evaluate the clinical efficacy of Huangkui Capsule combined with valsartan in the treatment of diabetic kidney disease by Meta-analysis.Material and method: Application of computer retrieval China Knowledge Network(CNKI),VIP database(VIP),Wanfang database,the Chinese biomedical literature database(SinoMed)and English database PubMed,back into the study of reference at the same time,comprehensive collection between January 2010 and January 2019 before the above database of published ambrette capsule combined valsartan clinical randomized controlled trials for the treatment of diabetic kidney disease.The bias risk assessment tool provided by Cochrane assistance network was used for quality evaluation,and the Meta analysis was conducted with RevMan5.3 software.The analysis indicators were continuous data,forest map and funnel map were drawn,and the analysis results were summarized and discussed.Results:1.A total of 27 clinical randomized controlled trials were included,and 27 of the literatures were in Chinese.A total of 2386 patients were included.2.Meta-analysis results showed that:(1)Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in 24 hours urine protein quantification compared with the control group(valsartan group): combined effect amount SMD =-1.68,95% CI(-2.46,-0.91),P < 0.0001.(2)Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in terms of urinary albumin excretion rate compared with the control group(valsartan group): combined effect amount SMD =-1.96,95% CI(-2.44,-1.49),P <0.00001.(3)Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in serum creatinine compared with the control group(valsartan group): combined effect amount SMD =-0.38,95% CI(-0.59,-0.18),P = 0.0003.(4)Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in the urea nitrogen compared with the control group(valsartan group): combined effect amount SMD =-0.43,95% CI(-0.86,-0.01),P = 0.04.(5)Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in terms of total cholesterol compared with the controlgroup(valsartan group): combined effect amount SMD =-1.42,95% CI(-1.88,-0.95),P<0.00001.(6)Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in the triglyceride compared with the control group(valsartan group): combined effect amount SMD =-0.90,95% CI(-1.21,-0.58),P <0.00001.Conclusion:Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease compared with valsartan alone,found that Huangkui capsule combined with valsartan in the treatment of diabetic kidney disease in 24 hours urine protein quantitation,urinary protein excretion rate,serum creatinine,triglyceride,total cholesterol Both are superior to valsartan alone.